More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/YC-1 [170632-47-0]
Chemical Structure
Chemical Structure
Chemical Structure

YC-1 [170632-47-0]

Research Use Only
AG-CR1-0120
AdipoGen Life Sciences
CAS Number170632-47-0
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight304.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    YC-1 [170632-47-0]
  • Delivery Days Customer
    10
  • CAS Number
    170632-47-0
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Molecular Formula
    C19H16N2O2
  • Molecular Weight
    304.4
  • Scientific Description
    Chemical. CAS: 170632-47-0. Formula: C19H16N2O2. MW: 304.4. Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator. Induces concentration-dependent increase in cGMP levels. Inhibits platelet adhesion to collagen. Thombosis inhibitor. Non-specific phosphodiesterase inhibitor. Na+ channel blocker. Anticancer compound. HIF-alpha inhibitor. Blocks angiogenesis. Tumor growth inhibitor. Apoptosis inducer. NK cell differentiation enhancer. TRAIL sensitizer. - Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator [1, 4]. Induces concentration-dependent increase in cGMP levels [1, 4]. Inhibits platelet adhesion to collagen [2, 8]. Thombosis inhibitor [3]. Non-specific phosphodiesterase inhibitor [5]. Na+ channel blocker [6, 9]. Anticancer compound [7, 8]. HIF-alpha inhibitor [7, 10]. Blocks angiogenesis. Tumor growth inhibitor [7, 10]. Apoptosis inducer [11]. NK cell differentiation enhancer [12]. TRAIL sensitizer [13].
  • SMILES
    OCC1=CC=C(O1)C1=NN(CC2=CC=CC=C2)C2=CC=CC=C12
  • Storage Instruction
    -20°C,2°C to 8°C
  • UNSPSC
    12352200

References

  • YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994)
  • YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995)
  • YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997)
  • Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998)
  • BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002)
  • Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002)
  • YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003)
  • Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review)
  • A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006)
  • Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007)